Predictive and prognostic markers in colorectal cancer

Area of Science:

• Oncology
• Cancer Therapeutics
• Molecular Diagnostics

Background:

• Colorectal cancer (CRC) is a leading cause of cancer diagnosis and mortality.
• 5-fluorouracil (5-FU) has been a primary treatment, but newer agents and targeted therapies show improved response rates.
• Significant challenges remain, including patient response variability, severe toxicities, and limited benefit for some.

Purpose of the Study:

• To review predictive and prognostic markers for colorectal cancer (CRC) treatment.
• To assess the robustness of individual markers in predicting treatment response and toxicity.
• To explore the development of multimarker profiles for personalized CRC therapy.

Main Methods:

• Review of existing literature on predictive and prognostic markers in colorectal cancer (CRC) treatment.
• Analysis of the clinical utility of individual markers for response, toxicity, and recurrence.
• Discussion of the potential of multimarker profiles for enhanced predictive accuracy.

Main Results:

• Current therapeutic options for advanced colorectal cancer (CRC) include 5-FU, oxaliplatin, irinotecan, and monoclonal antibodies.
• While response rates have improved, many patients experience toxicity or derive limited benefit.
• The utility of single markers for predicting response and toxicity is often limited, prompting research into multimarker approaches.

Conclusions:

• Accurate identification of patients likely to respond to specific therapies and experience toxicities is essential for optimizing CRC treatment.
• Multimarker profiles hold promise for more precise prediction of treatment outcomes in colorectal cancer (CRC).
• Further research is needed to validate these markers and integrate them into clinical decision-making for personalized cancer care.